Ghana Pharmaceutical Manufacturing Policy: How Ghana Plans to Produce More of Its Own Medicines

Ghana has launched a new Pharmaceutical Manufacturing Policy designed to dramatically increase the amount of medicine produced inside the country, reduce dependence on imported drugs and build Ghana into a pharmaceutical manufacturing hub for West Africa.

The Cabinet-approved policy was formally launched in Accra on October 28, 2026 by Minister for Trade, Agribusiness and Industry Elizabeth Ofosu-Adjare. Ghana currently produces roughly 30% of the medicines consumed domestically and imports approximately 70%. Under the new policy, the government wants local production to rise initially to around 60%, with a longer-term ambition of reaching approximately 70% pharmaceutical self-sufficiency.

The strategy goes much further than encouraging existing factories to make more tablets and capsules. Ghana wants to manufacture active pharmaceutical ingredients, vaccines, excipients and more complex pharmaceutical products, while expanding research, improving manufacturing standards, creating shared industrial infrastructure, providing manufacturers with longer-term financing and using government purchasing power to create a reliable market for medicines made in Ghana.

If successfully implemented, the policy could reshape Ghana’s healthcare supply chain and create a much larger pharmaceutical manufacturing industry. However, the targets are policy goals rather than production levels Ghana has already achieved, and substantial investment, regulatory work, infrastructure and manufacturing capacity will be required to reach them.

What Is Ghana’s New Pharmaceutical Manufacturing Policy?

The Ghana Pharmaceutical Manufacturing Policy, or GPMP, is a national framework for expanding pharmaceutical production inside Ghana. It is intended to coordinate areas that have often been treated separately, including investment, regulation, financing, research, workforce development, government procurement, industrial infrastructure and access to regional markets.

The Ministry of Trade says the goal is to create a pharmaceutical industry capable of supplying a much larger share of Ghana’s own medicines while also manufacturing products for export. The government wants Ghana to develop beyond relatively basic pharmaceutical production and become capable of manufacturing more technologically demanding products.

The policy is therefore both a health-security initiative and an industrialization strategy. The government is attempting to reduce vulnerability to international supply disruptions while creating factories, technical jobs, exports and investment inside Ghana.

How Much Medicine Does Ghana Import?

Approximately 70% of medicines used in Ghana are imported, according to government officials and the World Health Organization. Local manufacturers account for roughly 30% of domestic medicine supply.

The dependence becomes even greater further up the pharmaceutical supply chain. Ministry of Health officials said in October 2026 that Ghana imports almost 100% of the active pharmaceutical ingredients used by domestic manufacturers. That means even many medicines described as locally manufactured still depend heavily on imported chemical or biological ingredients.

WHO’s Vax & Pharm Ghana project similarly identifies Ghana’s high dependence on imported medicines as a health-security weakness. Ghana also currently depends heavily on imported human vaccines, making vaccines another major area targeted for domestic manufacturing expansion.

The Pharmaceutical Manufacturers Association has estimated that Ghana’s pharmaceutical import bill has risen significantly over the past decade. At the October 2026 policy launch, industry representatives said pharmaceutical imports that were worth roughly US$250 million about a decade ago had climbed to slightly above US$750 million annually.

What Do Ghana’s 60% and 70% Pharmaceutical Targets Mean?

Two different percentages have appeared in government statements, but they describe different stages of the same strategy. The Pharmaceutical Manufacturing Policy seeks to raise the share of locally manufactured medicines in Ghana’s domestic market from roughly 30% to 60% as an intermediate objective.

Government officials have also described a longer-term target of approximately 70% local pharmaceutical self-sufficiency. Presidential Coordinator for the Ghana Pharmaceutical Hub Dr. Bernice Makafui Brempong has described the ambition as reversing the existing situation so that Ghana produces around 70% of what it currently largely imports.

These percentages should be treated as national targets rather than guaranteed outcomes on a fixed date. The government will need substantial private investment, new factories, regulatory approvals, skilled personnel and reliable demand before local manufacturers can supply that share of the market.

What Does the Ghana Pharmaceutical Manufacturing Policy Actually Do?

The Ministry of Trade identified six major policy areas aimed at creating an environment in which Ghanaian pharmaceutical manufacturers can expand. Rather than relying on a single intervention, the framework combines manufacturing standards, market access, financing, investment, research and workforce development.

Key areas include:

• Improving the quality of medicines manufactured in Ghana.
• Helping manufacturers meet international production standards.
• Expanding market access for Ghanaian pharmaceutical companies.
• Providing affordable long-term financing for factories and equipment.
• Using public procurement to support qualified locally manufactured medicines.
• Developing pharmaceutical research and innovation.
• Expanding production of pharmaceutical raw materials and active ingredients.
• Supporting vaccine manufacturing.
• Strengthening pharmaceutical skills and industrial training.
• Encouraging contract manufacturing.
• Increasing exports through ECOWAS and the African Continental Free Trade Area.

The policy also provides the broader government framework behind Ghana’s emerging pharmaceutical hubs and industrial parks, where manufacturers are expected to share costly infrastructure rather than every company having to build everything independently.

Ghana Wants to Manufacture Active Pharmaceutical Ingredients

One of the most significant parts of the policy is the plan to develop domestic production of active pharmaceutical ingredients, commonly called APIs. An API is the component in a medicine that produces its therapeutic effect.

A Ghanaian factory may currently manufacture tablets or capsules locally while importing the API that actually makes the medicine work. That means the country can still be vulnerable to overseas shortages, shipping delays, currency movements and export restrictions even when the final medicine is produced in Ghana.

Government officials say Ghana currently imports almost all of its APIs. The new strategy seeks to move the pharmaceutical industry further upstream so that at least some of these critical ingredients can eventually be manufactured domestically.

The challenge is substantial. API production generally requires specialized chemical or biological manufacturing facilities, strict contamination controls, highly trained personnel, reliable utilities and significant capital investment. Ghana is therefore not expected to eliminate API imports immediately, but developing domestic capacity in selected products could reduce reliance on foreign suppliers.

Ghana Also Wants to Produce Pharmaceutical Excipients and Raw Materials

Active ingredients are only one part of a medicine. Manufacturers also use excipients, which are substances added to pharmaceutical products to help create tablets, capsules, syrups and other dosage forms.

Officials associated with the Ghana Pharmaceutical Hub say the strategy includes local production of materials such as pharmaceutical-grade corn starch, corn syrup and ethyl alcohol. This creates a potential connection between Ghana’s agricultural sector and pharmaceutical manufacturing.

Producing suitable pharmaceutical-grade ingredients is more demanding than simply producing the same agricultural commodity for food use. Materials used in medicines must meet defined purity, consistency and quality standards before pharmaceutical manufacturers can use them.

Vaccine Manufacturing Is a Major Part of Ghana’s Strategy

Ghana’s pharmaceutical policy also identifies vaccines as a strategic manufacturing priority. The country has already created the National Vaccine Institute and developed a 10-year vaccine manufacturing roadmap with support from international partners.

The World Health Organization says Ghana currently relies on imported vaccines and established the Vax & Pharm Ghana Project with the government and European Union to strengthen the systems required for domestic production. That programme covers manufacturing capacity, regulation, workforce skills and compliance with international standards.

In October 2026, the National Vaccine Institute also announced the establishment of an advanced mRNA laboratory at the Noguchi Memorial Institute for Medical Research. The laboratory is intended to strengthen Ghana’s research and development capabilities in next-generation vaccine technologies.

Research infrastructure should not be confused with commercial vaccine production. Establishing an mRNA laboratory does not mean Ghana is already mass-producing mRNA vaccines. Commercial production requires additional manufacturing facilities, validated processes, regulatory approval and quality-assurance systems.

How the Ghana Pharmaceutical Park Fits Into the Policy

The new manufacturing policy connects directly with Ghana’s efforts to build dedicated pharmaceutical industrial infrastructure. One of the most important projects is the Legon Pharmaceutical Innovation Park, or LePIP, being developed under the 24-Hour Economy and Accelerated Export Development Programme.

The planned ecosystem covers approximately 2,000 acres, beginning with a roughly 40-hectare pilot pharmaceutical manufacturing platform in the Osudoku/Ningo Prampram area of Greater Accra. Prospective businesses include manufacturers of conventional medicines, active pharmaceutical ingredients, vaccines, biologics, nutraceuticals, herbal medicines, diagnostics and medical devices.

LePIP is intended to provide infrastructure that individual pharmaceutical businesses may find expensive to develop alone, including reliable electricity and water, centralized quality-control laboratories, cold-chain facilities, warehousing, effluent treatment, regulatory support, logistics services and factory shells.

The first phase has been projected to support more than 3,000 direct jobs, while later phases have been associated with approximately 30,000 additional jobs. Those figures are project employment projections rather than currently available vacancies.

Why Shared Pharmaceutical Facilities Matter

Building a modern pharmaceutical factory can require significant investment before a single commercial product is sold. Companies need specialized clean rooms, quality-control laboratories, controlled utilities, environmental systems, manufacturing equipment, validation systems and trained technical personnel.

The government’s hub strategy attempts to reduce some of those barriers through shared facilities and contract manufacturing. Smaller companies that cannot afford a complete manufacturing plant could potentially use common infrastructure or contract with another qualified manufacturer to produce medicines.

Officials have also described plans for a pharmaceutical hub phase in the Central Region focused on APIs, herbal and plant-based medicines, raw materials, packaging and bioavailability and bioequivalence testing. Implementation details for the different pharmaceutical hub and industrial park components are expected to continue developing as the policy moves from planning into investment.

How Ghana Plans to Finance Pharmaceutical Manufacturing

Access to long-term capital remains one of the biggest obstacles facing Ghana’s pharmaceutical manufacturers. Pharmaceutical production requires expensive factories, specialized equipment, regulatory compliance and working capital, while some investments may take years to generate returns.

The new policy seeks to improve manufacturers’ access to long-term financing through partnerships involving institutions including Development Bank Ghana and Ghana EXIM Bank. Government officials also want the policy itself to make pharmaceutical projects more attractive to development finance institutions by showing that local production has formal national backing.

The financing gap is particularly important as companies move beyond conventional tablets and capsules into injectables, biological products, vaccines and APIs. Industry representatives have said Ghanaian manufacturers need significantly more capital to build the factories required for these products.

The National Vaccine Institute, for example, said in October that two private manufacturers and their partners, Atlantic Lifesciences and DEK Vaccines, require at least US$100 million to build and equip their planned facilities. This illustrates the scale of capital required to move from policy ambition to actual pharmaceutical production.

Government and NHIS Purchasing Could Support Medicines Made in Ghana

Building pharmaceutical factories is only useful if manufacturers have reliable markets for their products. The new policy therefore includes government procurement as one of the tools for expanding domestic production.

The government intends to use public purchasing and the National Health Insurance Scheme to give greater consideration to quality medicines produced locally. Hospitals, health programmes and other public-sector buyers represent a significant market, so predictable procurement can give manufacturers greater confidence when investing in additional production capacity.

This does not mean locally manufactured medicine can automatically be purchased regardless of quality or price. Government officials have repeatedly emphasized that domestic products must meet appropriate safety, efficacy and quality standards.

Ghana Wants Local Manufacturers to Meet International Pharmaceutical Standards

Increasing production is only one part of the policy. Ghana also wants locally manufactured medicines to meet standards that allow them to compete domestically and internationally.

The government plans to support companies pursuing Good Manufacturing Practice, or GMP, compliance and relevant World Health Organization standards. GMP requirements cover areas such as factory design, equipment, documentation, contamination prevention, quality assurance, employee training and consistent manufacturing procedures.

WHO prequalification can be particularly important for companies seeking access to international procurement markets. Products meeting international quality requirements may have greater opportunities to participate in procurement by global health organizations and supply other countries.

This is also critical to consumer confidence. Expanding domestic production will only improve medicine security if locally manufactured products remain safe, effective and consistently produced.

Research and Universities Are Part of the Pharmaceutical Strategy

The policy seeks stronger collaboration between pharmaceutical manufacturers, universities and research institutions. Ghana wants academic programmes and scientific research to align more closely with the skills and technologies pharmaceutical companies actually require.

Government officials have specifically discussed developing pharmacists for industrial manufacturing roles rather than concentrating almost exclusively on community and hospital pharmacy. The pharmaceutical hub initiative is also expected to support research, formulation development, testing and collaboration between industry and academic institutions.

LePIP includes plans for a Pharmaceutical Manufacturing Centre of Excellence in partnership with the University of Ghana. The programme has been projected to supply more than 1,000 industry-ready workers during its first five years.

What Pharmaceutical Jobs Could Be Created in Ghana?

A larger manufacturing industry could create employment across a much wider range of occupations than pharmacists alone. Pharmaceutical factories require production operators, industrial pharmacists, microbiologists, chemists, biochemists, engineers, laboratory technicians, quality-assurance staff, regulatory specialists, maintenance workers, supply-chain professionals and administrative personnel.

Additional jobs could emerge in packaging, cold-chain logistics, warehousing, transportation, agricultural inputs, construction, equipment servicing and pharmaceutical research. Government officials have also identified approximately 1,600 unemployed pharmacists as a group that could benefit from expansion of industrial pharmacy.

Job projections associated with individual pharmaceutical parks should not be confused with vacancies currently accepting applications. Employment will develop as individual manufacturers establish operations, construct factories and begin production.

Could Ghana Become a Pharmaceutical Manufacturing Hub for West Africa?

The policy is not designed solely around Ghana’s domestic population. The government wants pharmaceutical companies operating in Ghana to sell medicines throughout West Africa and eventually compete in wider African and international markets.

Two important markets are the Economic Community of West African States, or ECOWAS, and the African Continental Free Trade Area, or AfCFTA. Ghana’s position as host of the AfCFTA Secretariat also strengthens the government’s interest in making the country a regional manufacturing base.

Export success will depend heavily on price, production scale, product registration, regulatory recognition, logistics and manufacturing quality. Ghanaian factories will have to compete with established pharmaceutical producers from Africa, Asia, Europe and other regions rather than relying solely on government policy.

If manufacturers can meet those requirements, however, regional exports could allow Ghanaian factories to operate at a much larger scale than would be possible if they served only the domestic market.

Will Manufacturing More Medicines in Ghana Make Drugs Cheaper?

Local production could reduce some costs associated with importing finished pharmaceutical products, but it does not automatically guarantee lower medicine prices. Manufacturing costs depend on factory scale, financing, electricity, imported inputs, regulatory compliance, transportation, taxes and the cost of APIs and other raw materials.

If Ghana continues importing nearly all active ingredients, local manufacturers can still be exposed to foreign exchange movements even when final production occurs domestically. Developing local APIs and pharmaceutical-grade raw materials could reduce some of that exposure over time, but Ghana is still at an early stage of building those capabilities.

The strongest immediate argument for increased domestic production is therefore medicine security and supply-chain resilience. Price improvements may follow where production becomes competitive and efficient, but they will depend on the economics of individual products.

Why Ghana Considers Medicine Manufacturing a National Security Issue

The COVID-19 pandemic demonstrated what can happen when countries depend heavily on overseas manufacturers for medicines, vaccines and medical supplies. Export restrictions, international competition, factory disruptions and transportation problems can interrupt access even when a country has the money to purchase products.

WHO’s Vax & Pharm Ghana programme specifically identifies Ghana’s import dependence as a source of vulnerability. Expanding domestic capacity gives the country more ability to produce certain essential products during emergencies rather than relying entirely on foreign supply chains.

That does not mean Ghana will stop importing medicines. Even countries with large pharmaceutical industries participate extensively in international pharmaceutical trade. The policy is instead designed to give Ghana greater domestic capacity in strategically important products while reducing excessive dependence on imports.

What Could Prevent Ghana From Reaching 60% or 70% Local Pharmaceutical Production?

The targets are ambitious, and announcing a policy does not automatically create manufacturing capacity. Ghana will have to overcome several structural challenges if local producers are to supply most of the country’s medicines.

Major challenges include:

• High cost of constructing GMP-compliant pharmaceutical factories.
• Limited access to affordable long-term financing.
• Heavy reliance on imported APIs and pharmaceutical raw materials.
• Foreign exchange risk.
• Cost and reliability of electricity and other utilities.
• Need for specialized pharmaceutical manufacturing skills.
• Regulatory approval requirements.
• Competition from large overseas pharmaceutical manufacturers.
• Need for predictable government procurement.
• Achieving sufficient production scale to remain competitive.
• Maintaining international manufacturing and quality standards.
• Building export distribution networks.

The policy attempts to address many of these problems simultaneously, which is why financing, industrial parks, research, procurement, training and manufacturing standards are all included rather than relying on a single subsidy or government programme.

How Will We Know Whether the Policy Is Working?

The clearest measure will not be the number of policy announcements but actual manufacturing output. Ghana’s pharmaceutical coordinator has said implementation should ultimately be measured by factories established, investments attracted, medicines produced, jobs created and the competitiveness of domestic manufacturers.

Other useful indicators will include the percentage of medicines supplied locally, reduction in pharmaceutical imports, number of internationally certified factories, value of pharmaceutical exports, volume of APIs and excipients produced domestically, vaccine manufacturing milestones and private capital invested in the industry.

GhanaCitizenship.com will continue updating this guide as manufacturing projects move from policy announcements into construction and actual production.

What Happens Next?

The launch of the Pharmaceutical Manufacturing Policy establishes the national framework, but implementation will now determine whether Ghana reaches its manufacturing targets. The next important developments will involve investment commitments, factory construction, financing agreements, regulatory approvals and actual increases in locally manufactured products.

Key developments to watch include:

• New pharmaceutical factories entering construction.
• LePIP tenants establishing manufacturing operations.
• Commercial API production beginning in Ghana.
• Domestic production of pharmaceutical-grade excipients.
• Progress at Ghana’s planned vaccine manufacturing facilities.
• WHO GMP certification and prequalification of Ghanaian manufacturers.
• Government procurement rules favoring qualifying local products.
• Long-term pharmaceutical financing programmes.
• Growth in pharmaceutical exports through ECOWAS and AfCFTA.
• Changes in the local-versus-imported medicine share.

Bottom Line

Ghana’s new Pharmaceutical Manufacturing Policy represents one of the country’s most comprehensive attempts to reduce its dependence on imported medicines. Ghana currently manufactures only about 30% of the medicines it uses and imports roughly 70%, while almost all active pharmaceutical ingredients used by domestic manufacturers are sourced internationally.

The immediate policy objective is to increase locally manufactured medicines toward approximately 60% of domestic supply, while the government has articulated a longer-term ambition of around 70% local pharmaceutical self-sufficiency. Achieving that goal will require substantially more than expanding production of existing tablets and capsules.

Ghana wants to develop API manufacturing, vaccine production, pharmaceutical raw materials, contract manufacturing, research, shared industrial infrastructure and internationally competitive factories. Government procurement, the National Health Insurance Scheme, Development Bank Ghana, Ghana EXIM Bank, universities and the private pharmaceutical industry are all expected to play roles.

The Pharmaceutical Manufacturing Policy also provides the policy framework behind physical projects such as Ghana’s pharmaceutical hubs and the Legon Pharmaceutical Innovation Park. Together, the policy and industrial infrastructure are intended to move Ghana from being predominantly an importer of medicines toward becoming a major pharmaceutical manufacturing and export base in West Africa.

The targets remain ambitious and should not be interpreted as already achieved. The real test will be whether the policy produces operating factories, internationally compliant medicines, domestic pharmaceutical ingredients, competitive exports and a measurable reduction in Ghana’s dependence on imported medicines over the coming years.

Sources

• MyJoyOnline: Trade Ministry launches pharmaceutical policy to double local medicine production, October 29, 2026
• MyJoyOnline: Government targets 70% local medicine production as manufacturers seek funding, October 30, 2026
• MyJoyOnline: Ghana plans local production of active pharmaceutical ingredients to cut drug imports, October 29, 2026
• MyJoyOnline: Pharmaceutical Hub initiative targets import dependence, November 2, 2026
• World Health Organization Africa: Vax & Pharm Ghana Project Brief
• 24-Hour Economy Secretariat: Legon Pharmaceutical Innovation Park
• MyJoyOnline: National Vaccine Institute mRNA laboratory, October 29, 2026